Arch Therapeutics Co-Founder Dr. Ellis-Behnke Speaks at 6th Annual CLINAM Nanomedicine Summit in Basel, Switzerland

Arch Therapeutics Co-Founder Dr. Ellis-Behnke Speaks at 6th Annual CLINAM 
Nanomedicine Summit in Basel, Switzerland 
Company Views Participation at Forefront of Emerging Trends in
Nanomedicine as Important to Ongoing Strategy for Success 
CAMBRIDGE, MA -- (Marketwired) -- 07/23/13 --   Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company
and developer of AC5(TM), a novel product aimed at controlling
bleeding and fluid loss in order to provide faster and safer surgical
and interventional care, is pleased to advise that co-founding and
inventing scientist, Dr. Rutledge Ellis-Behnke, delivered a lecture
titled "The Spider Effect, how the Immune System in the Brain can be
Measured and Modulated with Nanotechnology" at the 6th annual
European Foundation for Clinical Nanomedicine (CLINAM) Summit in
Basel, Switzerland. 
The focus of this year's CLINAM Summit was 'Nanomedicine & Targeted
Medicine -- the paradigm of precise, highly effective and safe
medicine with subtle influence for the benefit of patients and
mankind.' Beat Loeffler, Executive Director of CLINAM, said the goal
of the 2013 Summit was "to bring together the most skilled people in
an effort to help to shape this scientific field and thereby push the
boundaries of cutting-edge Nanomedicine and Targeted Medicine." 
Ellis-Behnke, a founding board member of the International Society of
Nanomedicine, discussed the groundbreaking system he designed to
categorize the activation status of microglia using morphological
attributes. "The work represents a new measurement system for
inflammation that assigns an objective number to the level of
inflammation and thus can be used as a diagnostic to treat and
measure the response," he said. 
Ellis-Behnke noted, "Inflammation is often only treated for two
weeks. However, our work indicates that inflammation can last far
longer than that before returning to a resting state, suggesting that
inflammation needs to be treated far longer than was once thought. In
order to modulate these responses, it is important to control the
leakage of blood within and between tissue components as well as in
the local environment. This can be accomplished with novel
materials."  
Dr. Ellis-Behnke was instrumental in discovering the hemostatic and
other barrier properties of self-assembling peptides that could make
future surgery and interventional care faster and safer. He proposed
the development and commercialization of Arch Therapeutics' flagship
product candidate known as AC5(TM).  
Arch Therapeutics CEO, Dr. Terrence Norchi further comments, "Dr.
Ellis-Behnke is at the forefront of emerging trends in nanomedicine
and the advice he provides our Company continues to be of great
importance. He is the lead inventor on the intellectual property
exclusively licensed by Arch Therapeutics from the Massachusetts
Institute of Technology and his work offers strategic insights that
shape our future and the roadmap for our success." 
Additional details regarding Arch Therapeutics, Inc., its business,
agreements and related matters are filed as part of the Company's
continuous public disclosure as a reporting issuer under the
Securities Exchange Act of 1934 filed with the Securities and
Exchange Commission ("SEC"), and are available at the SEC's website
at www.sec.gov. For more information, visit our website at
www.archtherapeutics.com. 
About Arch Therapeutics, Inc. (OTCQB: ARTH)
 Arch Therapeutics, Inc.
(OTCQB: ARTH) is a medical device company developing a novel approach
to stop bleeding (hemostasis) and control leaking (sealant) during
surgery and trauma care. Arch's goal is to develop and commercialize
products based on our innovative technology platform that make
surgery and interventional care faster and safer for patients. Arch's
flagship development stage product candidate known as AC5(TM) is
being designed to elegantly achieve hemostasis in minimally invasive
and open surgical procedures. Find out more at
www.archtherapeutics.com.  
Notice Regarding Forward-Looking Statements
 This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and Section
21(e) of the Securities Exchange Act of 1934, as amended. Statements
in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding the future. Such
forward-looking statements include, among other things, references to
novel technologies and methods, our business and product development
plans and projections, or market information. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or technologies
and operating as a development stage company, our ability to retain
important members of our management team and attract other qualified
personnel, our ability to raise the additional funding we will need
to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements are
made as of the date of this news release, and we assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements. Although we believe that any beliefs,
plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein and
should also refer to the risk factors disclosure outlined in the
reports and other documents we file with the SEC, available at
www.sec.gov. 
On Behalf of the Board, 
Terrence W. Norchi, MD.
 Arch Therapeutics, Inc. 
Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com 
Website: www.archtherapeutics.com 
 
 
Press spacebar to pause and continue. Press esc to stop.